



Joint working executive summary

| | |
|-------------------------------|---|
| Project title | Executive Summary of a Joint Working Project between NHS Greater Glasgow & Clyde & Sanofi - Inpatient Diabetes Care within the Queen Elizabeth University Hospital |
| Partner organisation/s | NHS Greater Glasgow and Clyde – Queen Elizabeth University Hospital Sanofi |
| Project rationale | <p>At the time of the initiation of the project, on average over 370 in-patients in the Queen Elizabeth University Hospital, in NHS Greater Glasgow and Clyde, are patients who have Diabetes (17% of 2,200 beds). Complications arise with these inpatients on a daily basis, including delayed discharges, unnecessary admissions, unnecessary severe hypoglycaemia, development of neuropathic foot ulcers, serious medication errors (including insulin errors) and generally poor reported experience.</p> <p>There exists an opportunity to improve inpatient diabetes care within the Queen Elizabeth University Hospital. For this opportunity to be realised a significant gap in clinical education and in implementation, including undertaking the development of new in-patient pathways and structured in-patient therapy reviews, needs to be bridged.</p> <p>NHS Greater Glasgow & Clyde and Sanofi have developed a joint working project to support the above directive across the locality. The proposed two year joint working collaboration aims to:</p> <p>Reduce delayed discharges, unnecessary severe hypoglycaemic episodes, and harm from serious medication errors (including insulin errors), via the development of consistently high standards of multidisciplinary inpatient care throughout the Queen Elizabeth University Hospital.</p> |
| Project period | The Project is expected to run over 24 months from Q4 2018 to Q4 2020. |
| Project objectives | <ul style="list-style-type: none">• Patients can expect to and will benefit from more equitable and consistent care as well as improved education around hypoglycaemia. They will feel greater empowerment in managing aspects of their own healthcare and have better access to treatment options.• The Queen Elizabeth University Hospital and NHS Greater Glasgow and Clyde can expect to benefit from a higher quality and more consistent approach |

| | |
|-------------------------------|--|
| | <p>to care delivering a reduction in insulin errors, a reduction in patient length of stay and in frequency of in-patient hypoglycaemic episodes.</p> <ul style="list-style-type: none"> • Sanofi may benefit through the optimised use of medicines (some of which may be from the Sanofi portfolio), an improvement in corporate reputation and in relationships within the Health Board and from the opportunity to share a new best practice with other Health Boards. |
| <p>Contact details</p> | <p>NHS: Dr Steve Clelend, Consultant Diabetologist, Queen Elizabeth University Hospital, NHS GG&C, 1345 Govan Road, Glasgow, G51 4TF Tel - 07540 289689</p> <p>Sanofi: Fleur Chandler, Head of Market Access, Sanofi, 410 Thames Valley Park Drive Reading, Berks, RG6 1PT gb-marketaccess@sanofi.com</p> |